ATX Insider Trading (Amplia Therapeutics)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$240,617.17
Insider Selling (Last 12 Months): A$0.00
Amplia Therapeutics Share Price & Price History
Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET
Better Options For Trading!
From Tradewins | Ad
I know–you’ve heard options trading is tough, but is it really tougher than the market is right now?
NO! “Options Trading Made Easy” by pro-trader Chuck Hughes gives traders the best options in an unpredictable market…
Get your copy now!
>>>
Amplia Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/10/2022 | S Jane Bell | Insider | Buy | 127,136 | A$0.17 | A$21,613.12 | | |
| 12/20/2021 | S Jane Bell | Insider | Buy | 714,285 | A$0.15 | A$103,571.33 | | |
| 9/2/2021 | Jane Bell | Insider | Buy | 557,646 | A$0.21 | A$115,432.72 | | |
| 6/7/2021 | John Lambert | Insider | Exercise | 130,000 | A$0.16 | A$20,150.00 | | |
| 9/18/2020 | Robert Peach | Insider | Issued | 275,808 | A$0.13 | A$35,027.62 | | |
| 8/4/2020 | John Lambert | Insider | Issued | 120,000 | A$0.10 | A$12,000.00 | | |
| 7/13/2020 | Warwick Tong | Insider | Issued | 200,000 | A$0.10 | A$20,000.00 | | |
| 9/17/2019 | Robert Peach | Insider | Transfer | 56,000 | A$0.08 | A$4,480.00 | | |
| 8/2/2019 | Andrew Cooke | Insider | Issued | 63 | A$0.10 | A$5.99 | | |
This Options Expert is Giving Everything Away!
From Tradewins | Ad
Trading champion Chuck Hughes has exposed the strategies of successful traders and handing them over to new traders like you!
His guide “Options Trading Made Easy” now comes with a Trade of the Day from Chuck himself to help you develop a profitable, pro-level trading account!
Get your copy today!
SEC Filings (Institutional Ownership Changes) for Amplia Therapeutics (ASX:ATX)
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Read More on Amplia Therapeutics
Today's Range
Now: N/A
50 Day Range
MA: N/A
52 Week Range
Now: N/A
Volume
77,249 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Amplia Therapeutics?
